PRTK

Paratek Pharmaceuticals, Inc. [PRTK] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

PRTK Stock Summary

Top PRTK Correlated Resources

PRTK


Top 10 Correlated ETFs

PRTK


Top 10 Correlated Stocks

PRTK


In the News

04:05 05 Dec 2022 PRTK

Paratek Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference

BOSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announces that Evan Loh, M.D., chief executive officer, will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Wednesday, Nov. 30 at 9:15 a.m. ET.

06:48 05 Dec 2022 PRTK

Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Lags Revenue Estimates

Paratek (PRTK) delivered earnings and revenue surprises of -40.74% and 13.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

08:00 05 Dec 2022 PRTK

Paratek Pharmaceuticals to Present at the Credit Suisse 31st Annual Healthcare Conference

BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, announces that Evan Loh, M.D., chief executive officer, will present at the Credit Suisse 31st Annual Healthcare Conference held Nov. 7-10. Dr. Loh's presentation will be available on-demand beginning Nov. 8 under “Presentations & Events" in the Investors section of the company's website. https://www.paratekpharma.com/investor-relations About Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use. The company's lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights. Paratek is also conducting a Phase 2b study with NUZYRA in a rare disease, nontuberculous mycobacterial (NTM) pulmonary disease, caused by Mycobacterium abscessus complex. Paratek estimates this opportunity represents a potential $1 billion addressable market in the United States. Paratek exclusively licensed U.S. rights and rights to the greater China territory for Seysara® (sarecycline), a once-daily oral therapy for the treatment of moderate to severe acne vulgaris, to Almirall, LLC. Paratek retains the development and commercialization rights for sarecycline in the rest of the world. In 2019, Paratek was awarded a contract from the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA), now valued at up to $304 million, to support the development and U.S.-based manufacturing of NUZYRA for pulmonary anthrax. For more information, visit www.ParatekPharma.com or follow us on LinkedIn and Twitter. Forward Looking Statements This press release contains forward-looking statements. All statements, other than statements of historical facts, included in this press release are forward-looking statements, and are identified by words such as "advancing," "expect," "look forward," "anticipate," "continue," and other words and terms of similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and uncertainties. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements. Our actual results and the timing of events could differ materially from those included in such forward-looking statements as a result of these risks and uncertainties. These and other risk factors are discussed under "Risk Factors" and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2021 and our other filings with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein.

08:00 05 Dec 2022 PRTK

Paratek Pharmaceuticals to Report Third-Quarter 2022 Financial Results on Nov. 3

BOSTON, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Thursday, Nov. 3 at 4:30 p.m. ET to report its financial results for the third quarter of 2022. The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPharma.com. Domestic investors wishing to participate in the call should dial 800-458-4121 and international investors should dial +1-646-828-8193. The conference ID is 7165992. Investors can also access the event at: https://viavid.webcasts.com/starthere.jsp?ei=1577240&tp_key=22e88571f9. About Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use. The company's lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights. Paratek is also conducting a Phase 2b study with NUZYRA in a rare disease, nontuberculous mycobacterial (NTM) pulmonary disease, caused by Mycobacterium abscessus complex. Paratek estimates this opportunity represents a potential $1 billion addressable market in the United States. Paratek exclusively licensed U.S. rights and rights to the greater China territory for Seysara® (sarecycline), a once-daily oral therapy for the treatment of moderate to severe acne vulgaris, to Almirall, LLC. Paratek retains the development and commercialization rights for sarecycline in the rest of the world. In 2019, Paratek was awarded a contract from the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA), now valued at up to $304 million, to support the development and U.S.-based manufacturing of NUZYRA for pulmonary anthrax. For more information, visit www.ParatekPharma.com or follow us on LinkedIn and Twitter. About NUZYRA® NUZYRA (omadacycline) is a novel antibiotic with both once-daily oral and intravenous formulations for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). A modernized tetracycline, NUZYRA is specifically designed to overcome tetracycline resistance and exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypicals, and other drug-resistant strains. Please see full Prescribing Information for NUZYRA at www.NUZYRA.com . Forward Looking Statements This press release contains forward-looking statements. All statements, other than statements of historical facts, included in this press release are forward-looking statements, and are identified by words such as "advancing," "expect," "look forward," "anticipate," "continue," and other words and terms of similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and uncertainties. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements. Our actual results and the timing of events could differ materially from those included in such forward-looking statements as a result of these risks and uncertainties. These and other risk factors are discussed under "Risk Factors" and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2021 and our other filings with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein.

08:00 05 Dec 2022 PRTK

Paratek Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that Paratek President and Chief Commercial Officer Adam Woodrow will participate in a virtual fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference. The hybrid conference will be held from Sept. 12-14, with in-person participation held at the Lotte New York Palace Hotel. Mr. Woodrow's event will be available to view on-demand at: https://journey.ct.events/view/50615e23-aa8f-4cbd-b346-07b27991853f and under "Presentations & Events" in the Investors section of the company's website at https://www.paratekpharma.com/investor-relations beginning Sept. 12 at 7 a.m. ET and for the next 90 days. Members of Paratek's senior management team will be available for virtual one-on-one meetings on Sept. 12. About Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use. The company's lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights. Paratek is also conducting a Phase 2b study with NUZYRA in a rare disease, non-tuberculous mycobacterial (NTM) pulmonary disease, caused by Mycobacterium abscessus complex. Paratek estimates this opportunity represents a potential $1 billion addressable market in the United States. Paratek exclusively licensed U.S. rights and rights to the greater China territory for SEYSARA® (sarecycline), a once-daily oral therapy for the treatment of moderate to severe acne vulgaris, to Almirall, LLC. Paratek retains the development and commercialization rights for sarecycline in the rest of the world. In 2019, Paratek was awarded a contract from the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA), now valued at up to $304 million, to support the development of omadacycline for pulmonary anthrax and the U.S.-based commercial manufacturing of NUZYRA. For more information, visit www.ParatekPharma.com or follow us on LinkedIn and Twitter. Forward Looking Statements This press release contains forward-looking statements. All statements, other than statements of historical facts, included in this press release are forward-looking statements, and are identified by words such as "advancing," "expect," "look forward," "anticipate," "continue," and other words and terms of similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and uncertainties. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements. Our actual results and the timing of events could differ materially from those included in such forward-looking statements as a result of these risks and uncertainties. These and other risk factors are discussed under "Risk Factors" and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2021 and our other filings with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein.

10:27 05 Dec 2022 PRTK

Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q2 2022 Results - Earnings Call Transcript

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Sarah Higgins - VP, Controller and Interim Principal Financial & Accounting Officer Evan Loh - CEO & Director Adam Woodrow - President & Chief Commercial Officer Randall Brenner - Chief Development & Regulatory Officer Conference Call Participants Suji Jeong - Jefferies Antonio Arce - H.C. Wainwright & Co. Robert Hazlett - BTIG Operator Good day, and welcome to Paratek Pharmaceuticals Second Quarter 2020 Earnings Conference Call.

06:48 05 Dec 2022 PRTK

Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Tops Revenue Estimates

Paratek (PRTK) delivered earnings and revenue surprises of 5.71% and 3.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

04:05 05 Dec 2022 PRTK

Paratek Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022

BOSTON, July 25, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Wednesday, Aug. 3 at 4:30 p.m. ET to report its financial results for the second quarter of 2022.

07:00 05 Dec 2022 PRTK

What to Know About Buying Penny Stocks on June 22nd

Here's what you need to know about trading penny stocks on June 21st The post What to Know About Buying Penny Stocks on June 22nd appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

04:05 05 Dec 2022 PRTK

Paratek Pharmaceuticals to Present at the Jefferies 2022 Healthcare Conference

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that Evan Loh, M.D., chief executive officer, will participate in a fireside chat June 9 from 3:30 to 3:55 p.m. Eastern Time at the Jefferies Healthcare Conference in New York City.

PRTK Financial details

Company Rating
Neutral
Market Cap
119.43M
Income
-88.66M
Revenue
109.96M
Book val./share
-3.01
Cash/share
1.03
Dividend
-
Dividend %
-
Employees
207
Optionable
No
Shortable
Yes
Earnings
03 Nov 2022
P/E
-1.83
Forward P/E
-1.22
PEG
0.84
P/S
1.08
P/B
-0.71
P/C
2.09
P/FCF
-1.8
Quick Ratio
2.3
Current Ratio
3.11
Debt / Equity
-1.56
LT Debt / Equity
-1.56
-
-
EPS (TTM)
-1.72
EPS next Y
-1.76
EPS next Q
-0.43
EPS this Y
-45.18%
EPS next Y
2.6%
EPS next 5Y
2.6%
EPS last 5Y
-18.41%
Revenue last 5Y
59.48%
Revenue Q/Q
1.05%
EPS Q/Q
15.15%
-
-
-
-
SMA20
-35.69%
SMA50
-9.92%
SMA100
-5.63%
Inst Own
76.96%
Inst Trans
-0.3%
ROA
-56%
ROE
61%
ROC
-0.6%
Gross Margin
84%
Oper. Margin
-64%
Profit Margin
-81%
Payout
-
Shs Outstand
54.86M
Shs Float
42.66M
-
-
-
-
Target Price
20
52W Range
1.6-4.95
52W High
-46.25%
52W Low
+115%
RSI
39.41
Rel Volume
0.58
Avg Volume
389.8K
Volume
227.86K
Perf Week
0.94%
Perf Month
-29.28%
Perf Quarter
5.39%
Perf Half Y
6.97%
-
-
-
-
Beta
1.50598
-
-
Volatility
0.04%, 0.62%
Prev Close
-2.71%
Price
2.15
Change
-2.27%

PRTK Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
0.470.540.51.062.95
Net income per share
-3.32-3.57-3.93-2.19-1.34
Operating cash flow per share
-2.93-2.58-4.09-2.34-1.09
Free cash flow per share
-2.97-2.58-4.1-2.35-1.1
Cash per share
5.667.946.572.832.16
Book value per share
3.071.51-1.21-2.31-2.89
Tangible book value per share
3.041.48-1.23-2.33-2.91
Share holders equity per share
3.071.51-1.21-2.31-2.89
Interest debt per share
2.47.618.456.136.18
Market cap
419.85M208.93M110.18M286.69M164.77M
Enterprise value
443.62M390.91M268.61M432.01M340.14M
P/E ratio
-4.71-1.86-0.86-2.97-2.79
Price to sales ratio
33.2812.216.666.111.27
POCF ratio
-5.34-2.57-0.82-2.77-3.41
PFCF ratio
-5.27-2.57-0.82-2.76-3.39
P/B Ratio
5.094.39-2.78-2.8-1.29
PTB ratio
5.094.39-2.78-2.8-1.29
EV to sales
35.1622.8416.249.212.61
Enterprise value over EBITDA
-5.41-3.83-2.37-5.71-8.36
EV to operating cash flow
-5.65-4.82-2-4.18-7.05
EV to free cash flow
-5.57-4.81-2-4.16-6.99
Earnings yield
-0.21-0.54-1.17-0.34-0.36
Free cash flow yield
-0.19-0.39-1.22-0.36-0.3
Debt to equity
0.724.81-6.58-2.45-2
Debt to assets
0.50.841.161.581.69
Net debt to EBITDA
-0.29-1.79-1.4-1.92-4.31
Current ratio
9.5614.4110.066.854.86
Interest coverage
-16.65-9.48-7.05-3.73-2.36
Income quality
0.880.721.041.070.82
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
2.933.7201.910
Research and developement to revenue
4.763.362.390.510.23
Intangibles to total assets
0.010000
Capex to operating cash flow
0.010000.01
Capex to revenue
-0.090-0.01-0.010
Capex to depreciation
-0.880.060.18-0.65-0.95
Stock based compensation to revenue
1.341.490.860.220.11
Graham number
15.1511.0110.3410.679.33
ROIC
-0.58-0.37-0.51-0.49-0.27
Return on tangible assets
-0.55-0.38-0.51-0.55-0.32
Graham Net
2.79-0.07-1.9-3.05-4.21
Working capital
143.7M237.53M219.15M140.16M120.8M
Tangible asset value
81.51M46.75M-40.48M-103.09M-128.62M
Net current asset value
79.27M2.63M-47.37M-115M-159.56M
Invested capital
0.724.81-6.58-2.45-2
Average receivables
10.81M7.99M12.66M15.73M24.43M
Average payables
2.68M1.95M2.96M1.81M3.6M
Average inventory
0013.07M14.56M12.79M
Days sales outstanding
170.385.31211.42122.3892.87
Days payables outstanding
00431.2176.4991.42
Days of inventory on hand
001.21K614.1186.78
Receivables turnover
2.1468.741.732.983.93
Payables turnover
000.854.773.99
Inventory turnover
000.30.591.95
ROE
-1.08-2.363.250.940.46
Capex per share
-0.040-0.01-0.01-0.01

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric History 2021-09-302021-12-312022-03-312022-06-30 2022-09-30
Revenue per share
0.50.650.440.520.5
Net income per share
-0.37-0.66-0.34-0.33-0.38
Operating cash flow per share
0.53-0.4-0.37-0.27-0.23
Free cash flow per share
0.53-0.4-0.37-0.27-0.23
Cash per share
2.261.941.521.311.03
Book value per share
-2.13-2.6-2.69-2.82-3.01
Tangible book value per share
-2.15-2.61-2.71-2.83-3.03
Share holders equity per share
-2.13-2.6-2.69-2.82-3.01
Interest debt per share
5.265.295.014.954.78
Market cap
239.18M220.97M154.88M102.34M141.78M
Enterprise value
382.84M396.34M362.86M320.84M373.79M
P/E ratio
-3.29-1.71-2.16-1.45-1.7
Price to sales ratio
9.786.956.83.715.09
POCF ratio
9.11-11.16-8.1-7.06-11.42
PFCF ratio
9.11-11.16-8.09-7.06-11.42
P/B Ratio
-2.28-1.73-1.1-0.69-0.85
PTB ratio
-2.28-1.73-1.1-0.69-0.85
EV to sales
15.6612.4615.9411.6413.42
Enterprise value over EBITDA
-27.85-14.58-27.31-24.79-23.05
EV to operating cash flow
14.58-20.01-18.99-22.13-30.1
EV to free cash flow
14.58-20.01-18.95-22.13-30.1
Earnings yield
-0.08-0.15-0.12-0.17-0.15
Free cash flow yield
0.11-0.09-0.12-0.14-0.09
Debt to equity
-2.43-2-1.83-1.73-1.56
Debt to assets
1.581.691.821.912.06
Net debt to EBITDA
-10.45-6.45-15.65-16.88-14.31
Current ratio
5.254.864.624.243.11
Interest coverage
-3.14-6.22-3.06-2.9-3.64
Income quality
-1.440.611.070.820.59
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
0.320.330.330.280.3
Intangibles to total assets
0000.010.01
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00-0.2500
Stock based compensation to revenue
0.120.150.110.140.14
Graham number
4.216.194.564.595.06
ROIC
-0.09-0.18-0.1-0.1-0.14
Return on tangible assets
-0.1-0.18-0.11-0.11-0.13
Graham Net
-3.16-3.78-3.91-4.02-4.2
Working capital
123.86M120.8M104.45M97.67M82.37M
Tangible asset value
-105.82M-128.62M-141.13M-150.2M-166.98M
Net current asset value
-134.33M-159.56M-177.18M-185.29M-202.13M
Invested capital
-2.43-2-1.83-1.73-1.56
Average receivables
26.98M32.47M30.04M31.82M32.28M
Average payables
3.62M3.83M3.48M2.26M5.18M
Average inventory
10.95M12.05M12.91M13.08M16.92M
Days sales outstanding
81.4893.74111.73103.92105.82
Days payables outstanding
104.73102.9120.9941.64166.89
Days of inventory on hand
185.16210.22327.96241.38427.15
Receivables turnover
1.10.960.810.870.85
Payables turnover
0.860.870.742.160.54
Inventory turnover
0.490.430.270.370.21
ROE
0.170.250.130.120.13
Capex per share
00000

PRTK Frequently Asked Questions

What is Paratek Pharmaceuticals, Inc. stock symbol ?

Paratek Pharmaceuticals, Inc. is a US stock , located in Boston of Massachusetts and trading under the symbol PRTK

What is Paratek Pharmaceuticals, Inc. stock quote today ?

Paratek Pharmaceuticals, Inc. stock price is $2.15 today.

Is Paratek Pharmaceuticals, Inc. stock public?

Yes, Paratek Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap